Rapid and Simple Analysis of N-Aspartylchlor in E6 (Talaporfin) Using Fluorescence Microtiterplate and Its Application for Determination in Cells, Tissues and Blood


N-aspartylchlorin e6 (talaporfin) concentrations in cancer cells, mouse liver tissues, and human plasma specimens were determined with fluorescence microtiter plate analysis. Talaporfin standard curves were obtained in each of the sample specimens of cells, mouse tissues, or human plasma including serial concentration of talaporfin. The correlation co-efficiencies (r2) of talaporfin standard curves were 0.99-1.00, and the CV less than 5%. Talaporfin incorporation into cells of human breast cancer cell line MCF-7 after incubating with 25 μg/mL talaporfin for up to 24 h revealed that the t-max of the drug incorporation was approximately 5 h, and the maximum drug concentration incorporated was 25 μg/107 cells. Talaporfin incorporation into MCF-7 cells was significantly decreased in the presence of 3 μg/mL cyc-losporine (p < 0.05). Balb/c nu/nu mice implanted human cholangiocarcinoma NOZ cells in liver were administered intravenously 5mg/mouse of talaporfin, and the tissues of normal liver and tumor, as well as plasma specimens, were analyzed for talaporfin concentrations. The mean (SD) of talaporfin concentration in plasma after 30 min of administration was 41.6 (2.3) μg/mL, while the level decreased to undetectable concentrations 2 h after administration. In contrast, the talaporfin concentrations in normal and tumor tissues after 30 min of administration were 1.1-7.8 μg/g tissue, and the level slightly increased or was almost maintained for up to 2-4 h after administration. The heparinized blood of the healthy subjects was incubated with 25 μg/mL talaporfin for up to 24 h. The plasma talaporfin concentration did not significantly change during the incubation, and thus talaporfin appears not to be incorporated into the blood cells. We established rapid and simple analysis procedures of talaporfin in biological specimens using a fluorescence microtiter plate assay. Using this assay procedure, the unique pattern of talaporfin disposition and pharmacokinetics were revealed in human cancer cells, liver tissues of tumor bearing mice, and human blood.

Share and Cite:

H. Yokoyama, M. Ebara, F. Nakamura, A. Nanasawa, S. Tanaka, K. Onda, K. Sugiyama, K. Kasuya, G. Muhetaer, M. Shimazu and T. Hirano, "Rapid and Simple Analysis of N-Aspartylchlor in E6 (Talaporfin) Using Fluorescence Microtiterplate and Its Application for Determination in Cells, Tissues and Blood," Journal of Cancer Therapy, Vol. 3 No. 5, 2012, pp. 521-527. doi: 10.4236/jct.2012.35067.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Y. W. Kim, S. M. Bae, G. Battogtokh, H. J. Bang and W. S. Ahn, “Synergistic Anti-Tumor Effects of Combination of Photodynamic Therapy and Arsenic Compound in Cervical Cancer Cells: In Vivo and in Vitro Studies,” PLos One, Vol. 7, No. 6, 2012, p. e38583. doi:/10.1371/journal.pone.0038583
[2] P. Soergel, G. F. Dahl, M. Onsrud and P. Hillemanns, “Photodynamic Therapy of Cervical Intraepithelial Neoplasia 1-3 and HPV Infection with Methylaminolevulinate and Hexaminolevulinate-A Double-Blind, Dose-Finding Study,” Lasers in Surgery and Medicine, Vol. 44, No. 6, 2012, pp. 468-474. doi:/10.1002/lsm.22041
[3] R. P. Johnson, C. W. Chung, Y. I. Jeong, D. H. Kang, H. Suh and I. Kim, “Poly (L-Histidine)-Tagged 5-Aminolevulinic Acid Prodrugs: New Photosensitizing Precursors of Protoporphyrin IX for Photodynamic Colon Cancer Therapy,” International Journal of Nanomedicine, Vol. 7, 2012, pp. 2497-2512.
[4] M. E. Ortner, K. Caca, F. Berr, J. Liebetruth, U. Mansmann, D. Huster, W. Voderholzer, G. Schachschal, J. M?ssner and H. Lochs, “Successful Photodynamic Therapy for Nonresectable Cholangiocarcinoma: A Randomized Prospective Study,” Gastroenterology, Vol. 125, No. 5, 2003, pp. 1355-1363. doi:/10.1016/j.gastro.2003.07.015
[5] J. T. Lau, P. C. Lo, W. P. Fong and D. K. Ng, “A Zinc(II) Phthalocyanine Conjugated with an Oxaliplatin Derivative for Dual Chemo- and Photodynamic Therapy,” Journal of Medicinal Chemistry, Vol. 55, No. 11, 2012, pp. 5446-5454. doi:/10.1021/jm300398q
[6] C. B. Simone, J. S. Friedberg, E. Glatstein, J. P. Stevenson, D. H. Sterman, S. M. Hahn and K. A. Cengel, “Photodynamic Therapy for the Treatment of Non-Small Cell Lung Cancer,” Journal of Thoracic Disease, Vol. 4, No. 1, 2012, pp. 63-75.
[7] M. L. Davila, “Photodynamic Therapy,” Gastrointestinal Endoscopy Clinics of North America, Vol. 21, No. 1, 2011, pp. 67-79. doi:/10.1016/j.giec.2010.09.002
[8] J. M. Houle, N. Clervoix, S. Bain and J. Spénard, “Lack of Effect of Sex and Disease State on the Pharmacokinetics of Porfimer Sodium,” Clinical Pharmacokinetics, Vol. 45, No. 9, 2006, pp. 923-930.doi:/10.2165/00003088-200645090-00004
[9] P. Baas, I. van Mansom, H. van Tinteren, F. A. Stewart and N. van Zandwijk, “Effect of N-Acetylcysteine on Photofrin-Induced Skin Photosensitivity in Patients,” Lasers in Surgery and Medicine, Vol. 16, No. 4, 1995, pp. 359-367. doi:/10.1002/lsm.1900160407
[10] T. A. Katsumi, K. Aizawa, Y. Kuroiwa, K. Saito, Y. Kurata, Y. Ii, T. Okunaka, C. Konaka and H. Kato, “Photodynamic Therapy with a Diode Laser for Implanted Fibrosarcoma in Mice Employing Mono-L-As-partyl Chlorin E6,” Photochemistry and Photobiology, Vol. 64, No. 4, 1996, pp. 671-675. doi:/10.1111/j.1751-1097.1996.tb03122.x
[11] D. Kessel, “Pharmacokinetics of N-Aspartyl Chlorin E6 in Cancer Patients,” Journal of Photochemistry and Photobiology B: Biology, Vol. 39, 1997, pp. 81-83. doi:/10.1016/S1011-1344(96)00009-7
[12] X.-M. Hu, T. Hirano and K. Oka, “Arsenic Trioxide Induces Apoptosis Equally to T Lymphoblastoid Leukemia MOLT-4 Cells and P-gp Expressing Daunorubicin-Resistant MOLT-4 Cells,” Cancer Chemotherapy and Pharmacology, Vol. 51, No. 2, 2003, pp. 119-126. doi:/10.1007/s00280-003-0629-5
[13] K. Kasuya, M. Shimazu, M. Suzuki, Y. Kuroiwa, J. Usuda, T. Itoi, A. Tsuchida and T. Aoki, “Novel Photodynamic Therapy against Biliary Tract Carcinoma Using Mono-L-Aspartyl Chlorine E6: Basic Evaluationfor Its Feasibility and Efficacy,” Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 17, No. 3, 2010, pp. 313-321.doi:/10.1007/s00534-009-0246-8
[14] Z.-L. Liu, T. Hirano, S. Tanaka, K. Onda and K. Oka, “Persistent Reversal of P-Glycoprotein-Mediated Daunorubicin Resistance by Tetrandrine in Multidrug-Resistant Human T Lymphoblastoid Leukemia MOLT-4 Cells,” Journal of Pharmacy and Pharmacology, Vol. 55, No. 11, 2003, pp. 1531-1537. doi:/10.1211/0022357022115
[15] J. Usuda, S. Ichinose, T. Ishizumi, H. Hayashi, K. Ohtani, S. Maehara, S. Ono, H. Honda, N. Kajiwara, O. Uchida, H. Tsutsui, T. Ohira, H. Kato and N. Ikeda, “Outcome of Photodynamic Therapy Using NPE6 for Bronchogenic Carcinomas in Central Airways >1.0 cm in Diameter,” Clinical Cancer Research, Vol. 16, No. 7, 2010, pp. 2198-2204. doi:/10.1158/1078-0432.CCR-09-2520
[16] J. Usuda, S. Ichinose, T. Ishizumi, H. Hayashi, K. Ohtani, S. Maehara, S. Ono, H. Honda, N. Kajiwara, O. Uchida, H. Tsutsui, T. Ohira, H. Kato and N. Ikeda, “Breast Cancer Resistant Protein (BCRP) is a Molecular Determinant of the Outcome of Photodynamic Therapy (PDT) for Centrally Located Early Lung Cancer,” Lung Cancer, Vol. 67, No. 2, 2010, pp. 198-204. doi:/10.1016/j.lungcan.2009.04.002

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.